Cencora, Inc. (NYSE:COR) Shares Sold by Blair William & Co. IL

Blair William & Co. IL reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 0.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,567 shares of the company’s stock after selling 149 shares during the period. Blair William & Co. IL’s holdings in Cencora were worth $5,084,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of COR. Kingswood Wealth Advisors LLC acquired a new position in shares of Cencora in the 2nd quarter valued at $655,000. TD Asset Management Inc acquired a new position in Cencora in the first quarter valued at $95,313,000. LSV Asset Management acquired a new position in Cencora in the first quarter valued at $3,579,000. Cairn Investment Group Inc. purchased a new stake in Cencora during the first quarter valued at about $2,294,000. Finally, Lake Street Advisors Group LLC acquired a new stake in Cencora during the first quarter worth about $836,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of COR stock opened at $228.11 on Friday. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company’s fifty day moving average price is $234.84 and its two-hundred day moving average price is $233.11. The firm has a market capitalization of $45.50 billion, a P/E ratio of 24.96, a P/E/G ratio of 1.55 and a beta of 0.44. Cencora, Inc. has a 12 month low of $178.21 and a 12 month high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the prior year, the business posted $2.92 earnings per share. Cencora’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s payout ratio is currently 22.32%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COR. JPMorgan Chase & Co. lifted their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird reduced their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday. Bank of America restated a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a report on Wednesday. Finally, Leerink Partners reiterated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.67.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. Insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.